AACHEN, Germany--(EON: Enhanced Online News)--Hemovent GmbH, an emerging medical device company, announced today that it has filed two additional patents—for a gas exchanger and a pump—related to its novel and portable ExtraCorporeal Membrane Oxygenation (ECMO) device.
“We believe Hemovent’s ECMO system is designed for superior blood-handling and more consistently superior patient outcomes compared to standard ECMO”
“Although ECMO has proven to be an effective treatment for acute respiratory and circulatory failure, and although our system’s portability is very likely to expand the use of ECMO, we fully expect that our Hemovent system will mitigate many device-related complications in standard ECMO, such as hemolysis, that manifest due to flow-pressure rate issues and blood-clotting as a result of stagnant flow and insufficient washout zones,” said Oliver Marseille, Ph.D., co-founder and chief technology officer.
“We believe Hemovent’s ECMO system is designed for superior blood-handling and more consistently superior patient outcomes compared to standard ECMO,” added Dr. Marseille. “For these reasons, we expect that when Hemovent is available by mid-2018 it will drive ECMO usage not only for applications such as Extracorporeal Cardio Pulmonary Resuscitation (ECPR) but also as an effective therapy for other cardiac and respiratory failure indications.”
Dr. Marseille was a co-founder of CircuLite® (HeartWare® International) prior to co-founding Hemovent—which is developing the world’s smallest and first self-contained, fully portable ECMO system designed to support or replace heart and lung function in the event of cardiac and respiratory failure.
CAUTION: The Hemovent ECMO System is not approved for sale.